NanoViricides, Inc. reported that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV- 2 Oral Gummies. The Company is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, called "nanoviricides". NV-CoV-2, the Company's lead drug candidate for the treatment of coronavirus infections including COVID and potentially many cases of long COVID, has now entered Phase 1a/1b human clinical trials that are sponsored by Karveer Meditech Pvt.

Ltd. India, the Company's Licensee and co-developer in India. The Clinical Trial will Evaluate Both Safety and Initial Efficacy Indications in COVID patients: Phase 1a will assess the safety and tolerability of a new molecule (drug product NV-CoV-2 containing API NV-387) in healthy subjects. In Phase 1b, patients with mild to moderate COVID-19 will be enrolled to assess indication of efficacy.

Both oral drug products: (i") NV-CoV-2 oral Syrup, and (ii). NV-CoV-2O Oral Gummies are formulations of the same active pharmaceutical ingredient (API), NV-387. The Team Behind the Clinical Trials: The Company previously announced that it has executed a License Agreement with Karveer Meditech Privatet.

Ltd., Kolhapur, India ("Karveer"). To enable commercialization, Karveer has undertaken Clinical Development and Evaluation and is supporting these two drugs in India for this purpose. Karveer Meditech has retained the Clinical Trials Organization, PristynCR Solutions, Pvt.

Ltd., Aurangabad, India, to develop and prosecute the clinical trials applications and conduct the clinical trials. The Phase 1a/1b clinical trial labeled KM-NVCoV2-001 is being conducted at a single site, Clinical Research Unit in the Department of Clinical Pharmacology, Mahatma Gandhi Mission'sMedical College and Hospital, Aurangabad, India.